Iovance Biotherapeutics
Melissa Catlett is an experienced clinical science professional with a diverse background in the biotechnology and pharmaceutical industries. Currently serving as the Senior Director of Clinical Science at Iovance Biotherapeutics, Inc. since August 2021, Melissa has previously held roles such as Sr. Director, Clinical Research Scientist at Incyte from April 2018 to August 2021, and Clinical Scientist at Idera Pharmaceuticals from July 2017 to March 2018. Prior to this, Melissa's expertise was showcased at Merck Sharp and Dohme Corp as a Sr. Clinical Development Scientist between August 2014 and June 2017, and as a Sr. Clinical Research Specialist during an assignment at Amgen from November 2011 to August 2014. Earlier in their career, Melissa worked as a Clinical Scientist at Merck from 2003 to November 2011.
This person is not in any teams
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.